Shots:
- The Chinese NMPA has approved neffy 2mg for the emergency treatment of type I allergic reactions (anaphylaxis) in adults & children (≥30kg), with availability anticipated in the spring of 2026. Filing for neffy 1mg for children (15 to <30kg) to the NMPA is expected in the coming mos.
- In 2021, ARS Pharma licensed neffy to Pediatrix Therapeutics in China, earning a $4M final regulatory milestone, ~$80M in sales milestones & low double-digit royalties, while manufacturing & supplying the product
- neffy also secured Australian TGA approval with CSL Seqirus for emergency anaphylaxis treatment in adults & children ≥15kg, covering both 1 & 2mg doses, with New Zealand approval expected by the end of 2025
Ref: Globenewswire | Image: ARS Pharma | Press Release
Related News: ARS Pharmaceuticals and ALK’s EURneffy Secures the MHRA’s Approval to Treat Allergic Reactions in Children
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
